Can Namenda Cause Insomnia?
Yes, insomnia is a recognized adverse effect of memantine (Namenda), though it occurs at relatively low rates comparable to placebo in most controlled trials.
Evidence from FDA Drug Label
According to the official FDA drug label, insomnia was reported in controlled clinical trials but occurred at similar or lower rates in Namenda-treated patients compared to placebo 1. The label specifically lists insomnia among "other adverse events occurring with an incidence of at least 2% in Namenda-treated patients but at a greater or equal rate on placebo" 1. This indicates that while insomnia does occur in patients taking Namenda, it may not be directly caused by the medication in most cases.
However, the FDA label also notes that in post-marketing surveillance and clinical trials involving approximately 1,350 patients, insomnia was classified as an "infrequent" adverse event (occurring in 1/100 to 1/1000 patients) among psychiatric disorders 1. Additionally, "sleep disorder" was listed separately as an infrequent psychiatric adverse event 1.
Clinical Trial Evidence
The systematic review from the American College of Physicians found that reported adverse events in memantine trials included agitation (8-32% in placebo groups; 4-18% in treatment groups), but insomnia rates were not significantly different between groups 2. One specific study noted that adverse events with higher incidence in memantine recipients compared to placebo included diarrhea, insomnia, dizziness, headache, and hallucination in patients with moderately severe to severe dementia 3.
Case Reports of Sleep Disturbances
More concerning are recent case reports documenting specific sleep-related adverse effects:
A 2025 case report described a 49-year-old woman with Huntington's disease who developed delayed sleep phase disorder after starting memantine 4. The sleep disturbance was dose-dependent and reversible, confirmed by sleep logs and actigraphy 4.
A 2018 case report documented a 73-year-old patient who developed a manic episode after taking memantine, with insomnia being one of the common drug-induced adverse events mentioned 5.
Clinical Implications
Key Points:
- Insomnia occurs in a small percentage of patients taking Namenda (1-2% range)
- The incidence is generally similar to or lower than placebo in controlled trials
- However, individual patients may experience significant sleep disturbances, including delayed sleep phase
- Sleep problems appear to be dose-dependent and reversible upon discontinuation
Practical Recommendations:
- Monitor for new-onset sleep disturbances when initiating memantine
- If insomnia develops, consider timing of administration (morning dosing may be preferable)
- Assess whether sleep problems are dose-related and potentially reversible with dose reduction
- Document sleep patterns if insomnia is reported, as it may represent a circadian rhythm disorder rather than simple insomnia
- Consider discontinuation if sleep disturbances significantly impact quality of life
Common Pitfall:
Do not automatically attribute insomnia in dementia patients to memantine, as sleep disturbances are common in dementia itself and occurred at similar rates in placebo groups 1. However, remain vigilant for the rare but documented cases of memantine-induced circadian rhythm disorders that may present as insomnia.